Correct. Everyone seems to be misinterpreting what I posted.
My point isn't that AVXL should forego the Alzheimer's trial NDA if the data is positive. But if they have to run another Alzheimer's trial, I'd prefer for the company to spend its time and focus on bringing the drug to market sooner for another disease, such as Rett, and taking the low hanging fruit of a free $100mm rather than continue to spend money pursuing Alzheimer's.
Obviously if both can be done simultaneously that is the best option of all.
There were breathless claims that TGD was ingeniously timing everything like a maestro according to an obvious but secret plan of wonderfulness and riches for us. Turns out he's CEO of a biotech trying to get a couple of clinical trials done.
News 
Market Data 
Discover 
